Drug
Medisorb Naltrexone
Medisorb Naltrexone: highest development phase Phase 3, developed by Alkermes. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Alkermes
Trials
| Drug | Phase | Indication |
|---|---|---|
| Medisorb naltrexone 380 mg NCT00834080 | Phase 3 | Opiate Dependence |
| Medisorb naltrexone 190 mg NCT01218958 | Phase 3 | Alcoholism |
| Medisorb naltrexone 380 mg NCT00156923 | Phase 3 | Alcoholism |
| Medisorb naltrexone 75 mg NCT01218984 | Phase 2 | Opiate Dependence |
Latest
No recent events.
Follow Medisorb Naltrexone on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.